Fda grants rafael pharmaceuticals orphan drug designation for cpi-613® (devimistat) for treatment of biliary cancer

Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers

RFL Ratings Summary

RFL Quant Ranking